

Cytokeratin fraction 21-1 (CYFRA 21-1)

- Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer
- CYFRA 21-1 levels in cerebrospinal fluid as a putative therapeutic monitoring biomarker for patients with leptomeningeal carcinomatosis: A pilot study
- Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis
- Effects of thoracic paravertebral block on postoperative analgesia and serum level of tumor marker in lung cancer patients undergoing video-assisted thoracoscopic surgery
- The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer

CYFRA 21-1 has been widely studied as an important **biomarker** in **non-small cell lung cancer** for both **diagnosis** and **prognosis**. Many studies have also assessed the clinical applications of **CYFRA 21-1** in head and neck **cancer**, but the diagnostic and prognostic values of CYFRA 21-1 are not yet fully established.

A **pooled analysis** aimed to evaluate the diagnostic accuracy and prognostic applications of CYFRA 21-1 in patients with head and neck cancer. A systematic retrieval of **literatures** was conducted without time or language restrictions by searching **PubMed**, **EMBASE**, **Web of Science**, **Cochrane library** and **China National Knowledge Infrastructure**. Twenty studies were eligible for **systematic review**, of which 14 conformed for diagnostic analysis and 7 for prognostic analysis. The pooled sensitivity and specificity of CYFRA 21-1 analysis were 0.53 (95% CI: 0.39-0.67) and 0.97 (95% CI: 0.93-0.99), respectively. A high level of CYFRA 21-1 was significantly correlated with shorter **overall survival** (HR 1.33, 95% CI: 1.13-1.56) and disease-free survival (HR 1.48; 95%CI: 1.10-1.97). Current **evidence** indicates that the level of CYFRA 21-1 in the serum could be used as an indicator for monitoring tumor status and evaluating its curative effects ¹⁾.

¹⁾

Liu L, Xie W, Xue P, Wei Z, Liang X, Chen N. Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis. PLoS One. 2019 May 9;14(5):e0216561. doi: 10.1371/journal.pone.0216561. eCollection 2019. PubMed PMID: 31071161.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=cyfra_21-1

Last update: **2024/06/07 02:52**

